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Prostate cancer (PCa) remains a leading cause of mortality in US men and the prevalence continues to rise world-wide
especially in countries where men consume a ‘Western-style’ diet. Epidemiologic, preclinical and clinical studies suggest
a potential role for dietary intake on the incidence and progression of PCa. 'This minireview provides an overview of
recent published literature with regard to nutrients, dietary factors, dietary patterns and PCa incidence and progression.
Low carbohydrates intake, soy protein, omega-3 (w-3) fat, green teas, tomatoes and tomato products and zyflamend
showed promise in reducing PCa risk or progression. A higher saturated fat intake and a higher β-carotene status may
increase risk. A ‘U’ shape relationship may exist between folate, vitamin C, vitamin D and calcium with PCa risk. Despite
the inconsistent and inconclusive findings, the potential for a role of dietary intake for the prevention and treatment of
PCa is promising. The combination of all the beneficial factors for PCa risk reduction in a healthy dietary pattern may
be the best dietary advice. This pattern includes rich fruits and vegetables, reduced refined carbohydrates, total and
saturated fats, and reduced cooked meats. Further carefully designed prospective trials are warranted.
Keywords: Diet, Prostate cancer, Nutrients, Dietary pattern, Lifestyle, Prevention, Treatment, Nutrition, Dietary
intervention, ReviewIntroduction
Prostate cancer (PCa) is the second most common cancer
in men, with nearly a million new cases diagnosed world-
wide per year [1], with approximately a six-fold higher in-
cidence in Western than in non-Western countries. Diet,
lifestyle, environmental and genetic factors are hypothe-
sized to play a role in these differences. This review fo-
cuses on the latest evidence of the potential role of dietary
factors on PCa and includes epidemiologic and clinical
trial evidence for the impact of protein, fat, carbohydrate,
fiber, phytochemicals, other food components, whole
foods and dietary patterns on PCa incidence, development
and/or progression.
Data from meta-analyses or well-designed randomized
trials and prospective studies are emphasized in this re-
view. It should be noted that studies of dietary intake or
nutrition and cancer are often subject to various limita-
tions and thus complicate interpretation of results. For
example, when a study is designed to examine the effect* Correspondence: pao.hwa.lin@dm.duke.edu
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unless otherwise stated.of the amount of fat intake, alteration in fat intake inev-
itably will change intake of protein and/or carbohydrate,
and may change the intake of other nutrients as well. As
a result, it is difficult to attribute the effect to change in
fat intake alone. In addition, the impact of macronutrients
potentially involves aspects of both absolute quantity and
the type of macronutrients consumed. Both aspects may
potentially affect cancer initiation and/or development in-
dependently, but they are not always distinguishable in re-
search designs. Though this topic was recently reviewed
[2], given the extensive new literature on the topic, an up-
dated review is presented herein and a summary table is
provided for a quick reference (Table 1).
Nutrients
Carbohydrates
Given the hypothesis that insulin is a growth factor for
PCa, it has been hypothesized that reducing carbohydrates
and thus lowering serum insulin may slow PCa growth
[3]. Indeed, in animal models, either a no-carbohydrate
ketogenic diet (NCKD) [4,5] or a low-carbohydrate diet
(20% kcal as carbohydrate) has favorable effects on slow-
ing prostate tumor growth [6,7]. In human studies, ones is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Summary of nutrients and food factors with prostate cancer
Nutrient or food factor
and references
Preclinical study Epidemiological study Clinical study Summary
Carbohydrate [3-7] Low carbohydrate slowed tumor growth. Rare On-going Potential, awaits evidence from RCT
Protein [23-46] Soy protein slowed tumor progression.
Genistein inhibited PCa cell detachment,
invasion, and metastasis.
Mixed results in total protein, dairy, soy
intake.
Supplement of geneistein reduced PCa
progression.
Soy products showed potential benefit,
need more RCT to confirm.
Fat [47-84] Low fat reduced PCa risk, high fat
increased risk.
Mixed results. Saturated fat may increase
and plant fat decrease PCa risk. W-3 PUFA
may decrease risk.
Low fat plus w-3 PUFA reduced PCa pro-
liferation and CCP.
Further research needed to clarify role of
amount and type of total fat and fatty
acids.
Vitamin A [85-90] NA Higher serum β-carotene associated with
higher PCa risk.
β-carotene supplement increased PCa
risk.
Supplement not advised.
Folate [91-98] Folate depletion reduced tumor growth. Higher circulation folate associated with
higher PCa risk or lower PSA.
Supplement folate had no effect on PCa
risk.
Potential dual role of folate in prostate
carcinogenesis, needs further
examination.
Vitamin C [89] May slow tumor growth in vitro and
in vivo.
Rare Rare. One study showed no effect. May act both as pro-oxidant and
antioxidant. Needs clarification.
Vitamin D [100-114] May slow PCa progression. Serum vitamin D associated with a higher
or lower risk.
No impact of vitamin D supplement on
PSA or PCa risk.
A ‘U’ shaped relationship may exist
between vitamin D status and PCa.
Vitamin E [115-125] May slow PCa tumor growth. Some show no association between
vitamin E supplement and PCa risk.
400 IU supplement had no effect or
increased PCa risk, but 75 IU supplement
lowered risk.
Weak evidence of benefit, further
research should consider dosage also.
Vitamin K [126,127] Anti-tumor, chemo and potential
radiosensitizers.
Inverse relationship between vitamin K
and PCa incidence.
NA Inadequate evidence
Calcium [128-130] Rare Calcium intake increased or decreased
PCa risk.






Toenail selenium associated with reduced
advanced PCa risk.
Selenium supplement had no effect for
PCa chemoprevention, or increased high
grade PCa risk among men with high
selenium status.
Conflicting results, more research is
needed.
Silibinin [133-135] Inhibit PCa growth via EGFR, IGF-1R,
NF-kB, TGFβ2, and CAF-like markers.
NA NA Potential as chemopreventive agent,
awaits further research.
Curcumin [136,137] Inhibited proinflammatory NF-B, induced
apoptosis, slowed PCa growth.
NA NA Potential to slow PCa growth, awaits
further research.
Pomegranate [137-141] Inhibited PCa proliferation, angiogenesis. Pomegranate juice increased PSA
doubling time in one trial, but no
controls included. Another trial showed
no impact.
Weak evidence of benefit.
Green tea
[131,137,142-145]
Inhibited PCa growth, induced apoptosis,
decreased inflammation.
NA Green tea catechin or EGCG supplement
reduced PCa incidence or PSA.
Some evidence of benefit, more research
needed.
Resveratrol [137,146-151] Inhibited PCa growth in some but not all
studies.
NA NA Potential, awaits further study.
Zyflamend [152-157] Reduced PCa progression. NA Reduced risk among those with high
grade PCa.












Table 1 Summary of nutrients and food factors with prostate cancer (Continued)
Fruits and vegetables
[158-163]
Allium vegetable reduced PCa risk. Inverse relationship between total fruit
and vegetable intake and PCa risk.
Supplement of pomegranate, green tea,
broccoli, turmeric reduced PSA rise.
Moderate evidence, consistent with




Lycopene slowed PCa growth,
progression.
Higher lycopene intake or serum level
associated with lower PCa risk in some
studies.
Supplement lycopene lowered PSA, PCa
symptoms in some studies.
Moderate evidence, needs large RCT to
confirm.
Coffee [177-183] NA Inverse between coffee consumption and




NA High HEI associated with lower PCa risk.
Mediterranean diet may prevent PCa.
Western diet associated with higher PCa
risk and Asian diet opposite.
NA Promising. RCT needed.
CAF, cancer-associated fibroblasts; CCP, cell cycle progression; EGCG, epigallocatechin gallate; EGFR, epidermal growth factor receptor; HEI, Healthy Eating Index; IGF-1R, IGF1 receptor; NF-kB, nuclear factor kappa B;
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associated with increased risk of PCa [7]. In addition to
the amount of carbohydrates, type of carbohydrates may
impact on PCa but research has been inconclusive.
The potential to reduce PCa risk and progression via
impacting carbohydrate metabolism is actively being in-
vestigated with Metformin. Metformin reduced PCa cell
proliferation and delayed progression in vitro and in vivo,
respectively [8-10] and reduced incident risk and mortality
in humans [11-13]. Two single arm clinical trials also
showed a positive effect of metformin in affecting markers
of PCa proliferation and progression [14,15]. However,
other retrospective cohort studies have not supported
an effect of metformin on recurrence or incident risk of
PCa [16-22].
Despite the potential for reducing either total or sim-
ple carbohydrates in benefiting PCa control, evidence is
lacking from randomized controlled trials (RCT). Two
randomized trials are on-going examining the impact of
a low-carbohydrate diet (approximately 5% kcal) on the
PSA doubling time among PCa patients post radical pros-
tatectomy (NCT01763944) and on glycemic response
among patients initiating androgen deprivation therapy
(ADT) (NCT00932672 ). Findings from these trials will
shed light on the effect of carbohydrate intake on markers
of PCa progression and the role of reduced carbohydrate
intake on offsetting the side effects of ADT.
Protein
The ideal level of protein intake for optimal overall health
or prostate health is unclear. Despite the popularity of low
carbohydrate diets that are high in protein, recent human
studies reported that low protein intake was associated
with lower risk for cancer and overall mortality among
men 65 and younger. Among men older than 65, low pro-
tein intake was associated with a higher risk for cancer
and overall mortality [23]. In animal models the ratio be-
tween protein and carbohydrate impacted on cardiometa-
bolic health, aging and longevity [24]. The role of dietary
protein and the protein to carbohydrate ratio on PCa de-
velopment and progression requires further study.
Animal-based proteins
Studying protein intake, like all aspects of nutritional
science, can be challenging. For example, animal meat,
which is a source of protein in Western diets, is com-
posed not only of protein, but also of fat, cholesterol,
minerals and other nutrients. The amount of these nutri-
ents including fatty acids may vary from one animal meat
to the other. Previous studies in human have shown that
consumption of skinless poultry, which is lower in choles-
terol and saturated fat than many red meats, was not as-
sociated with the recurrence or progression of PCa [25].
However, consumption of baked poultry was inverselyassociated with advanced PCa [26,27], while cooked red
meat was associated with increased advanced PCa risk
[26,27]. Thus, how the food is prepared may modify its
impact on PCa risk and progression. Overall, fish con-
sumption may be associated with reduced PCa mortal-
ity, but high temperature cooked fish may contribute to
PCa carcinogenesis [28]. Thus, it may be advisable to
consume fish regularly but cooking temperature should
be kept moderate.
Dairy-based protein
Another common protein source is dairy products, such
as milk, cheese and yogurt. Previous studies have shown
that dairy increased overall PCa risk but not with aggres-
sive or lethal PCa [29,30]. In addition, both whole milk
and low-fat milk consumption were reported to either
promote or delay PCa progression [29,31]. In the Physi-
cians Health follow up cohort with 21,660 men, total
dairy consumption was found to be associated with in-
creased PCa incidence [32]. In particular, low fat or skim
milk increased low grade PCa, whereas whole milk in-
creased fatal PCa risk. Though the exact component(s)
of dairy products driving these associations is unknown,
the high concentrations of saturated fat and calcium
may be involved. A cross-sectional study of 1798 men
showed that dairy protein was positively associated with
serum IGF-1 [33] levels which may stimulate initiation
or progression of PCa. Thus, further research is needed
to clarify the relationship between dairy intake and PCa.
There is insufficient data to provide recommendations
specifically related to dairy or dairy protein and PCa risk
or progression.
Plant-based proteins
Soy and soy-based products are rich in protein and phy-
toestrogens that may facilitate PCa prevention, but its
role on PCa is unclear. In a study in mice, intake of soy
products was associated with decreased hepatic aroma-
tase, 5α-reductase, expression of androgen receptor and
its regulated genes, FOXA1, urogenital tract weight and
PCa tumor progression [34]. A recent randomized trial
of 177 men with high-risk disease after radical prostatec-
tomy found that soy protein supplementation for two
years had no effect on risk of PCa recurrence [35]. Al-
though epidemiological and pre-clinical studies [36,37]
support a potential role for soy/soy isoflavones in PCa
risk reduction or progression, a meta-analysis did not
find significant impact of soy intake in PSA levels, sex
hormone-binding globulin, testosterone, free testoster-
one, estradiol or dihydrotestosterone [38]. Another RCT
in patients before prostatectomy also did not find any ef-
fect of soy isoflavone supplement up to six weeks on
PSA, serum total testosterone, free testosterone, total es-
trogen, estradiol or total cholesterol [39]. Since most RCTs
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examination is needed.
Many studies have continued to examine the primary
isoflavone in soy, genistein, and its effect on PCa. The
potential for genistein to inihibit PCa cell detachment,
invasion and metastasis is reported [40]. Genistein may
modify glucose update and glucose transporter (GLUT)
expression in PCa cells [41], or exert its anti-tumor ef-
fect by down regulating several microRNAs [42]. Studies
using tumor cells and animal models suggest genistein
may compete with and block endogenous estrogens from
binding to the estrogen receptor, thereby inhibiting cellu-
lar proliferation, growth, and inducing differentiation and,
specifically, genistein may inhibit cell detachment, prote-
ase production, cell invasion and thus prevent metastasis
[36,40,43]. However, neither plasma nor urinary genistein
levels were associated with PCa risk in case control studies
[44,45]. In a phase 2 placebo-controlled RCT with 47
men, supplementation of 30 mg genistein for three to six
weeks significantly reduced androgen-related markers of
PCa progression [46]. In addition, genistein may be be-
neficial in improving cabazitaxel chemotherapy in meta-
static castration-resistant PCa [37]. Clinical studies are
warranted to further examine the role of soy and soy
isoflavones for PCa prevention or treatment. A defini-
tive recommendation regarding protein intake for PCa
prevention or treatment is not available yet.
Fat
Research findings examining fat consumption with PCa
risk or progression are conflicting. Both the total ab-
solute intake [47] of dietary fat and the relative fatty
acid composition may independently relate to PCa initi-
ation and/or progression. While animal studies repeat-
edly show that reducing dietary fat intake slows tumor
growth [48-50] and high fat diets, especially animal fat
and corn oil increase PCa progression [51], human data
are less consistent. Case–control studies and cohort
studies have shown either no association between total
fat consumption and PCa risk [52-55] or an inverse as-
sociation between fat intake and PCa survival, particu-
larly among men with localized PCa [47]. In addition, a
cross-sectional study showed that fat intake expressed
as percent of total calorie intake was positively associ-
ated with PSA levels in 13,594 men without PCa [56].
Given these conflicting data, it is possible that the
type of fatty acid [56] rather than total amount may
play an important role in PCa development and pro-
gression. A study found plasma saturated fatty acids to
be positively associated with PCa risk in a prospective
cohort of 14,514 men of the Melbourne Collaborative
Cohort Study [57]. In addition, another study found
that eating more plant-based fat was associated with re-
duced PCa risk [58]. These studies support the currentdietary guideline of eating less animal-based fat and
more plant-based fat.
The data regarding omega-6 (w-6) and omega-3 (w-3)
polyunsaturated fatty acid (PUFA) consumption and PCa
risk are also conflicting. While there are data to support
a link between increased w-6 PUFA intake (mainly de-
rived from corn oil) and risk of overall and high-grade
PCa [57,59], not all data support such a link [60]. In fact,
a greater polyunsaturated fat intake was associated with
a lower all cause mortality among men with nonmeta-
static PCa in the Health Professionals Follow-up study
[58]. The postulated mechanism linking w-6 PUFAs
and PCa risk is the conversion of arachidonic acid (w-6
PUFA) to eicosanoids (prostaglandin E-2, hydroxyeico-
satetraenoic acids and epoxyeicosatrienoic acids) leading
to inflammation and cellular growth [61]. Conversely, w-3
PUFAs, which are found primarily in cold water oily fish,
may slow growth of PCa through a number of mecha-
nisms [61-63]. In a study of 48 men with low risk PCa
under active surveillance, repeat biopsy in six months
showed that prostate tissue w-3 fatty acids, especially
eicosapentaenoic acid (EPA), may protect against PCa
progression [64]. In vitro and animal studies suggest that
w-3 PUFAs induce anti-inflammatory, pro-apoptotic, anti-
proliferative and anti-angiogenic pathways [65,66]. More-
over, a mouse study comparing various types of fat found
that only the fish oil diet (that is, omega-3 based diet)
slowed PCa growth relative to other dietary fats [67].
In regards to human data, a phase II randomized trial
showed that a low-fat diet with w-3 supplementation four
to six weeks prior to radical prostatectomy decreased
PCa proliferation and cell cycle progression (CCP) score
[62,68]. A low-fat fish oil diet resulted in decreased 15(S)-
hydroxyeicosatetraenoic acid levels and lowered CCP
score relative to a Western diet [69]. The potential ben-
efits of omega-3 fatty acids from fish are supported by
epidemiological literature showing that w-3 fatty acid in-
take was inversely associated with fatal PCa risk [70,71].
Despite the promise of omega-3 fatty acids, not all studies
agree. Supplementing 2 g alpha-linolenic acid (ALA) per
day for 40 months in 1,622 men with PSA <4 ng/ml did
not change their PSA [72]. However, another study found
that a high blood serum n-3 PUFA and docosapentaenoic
acid (DPA) was associated with reduced total PCa risk
while high serum EPA and docosahexaenoic acid (DHA)
was possibly associated with increased high-grade PCa
risk [73]. Further research is required to understand
better the role of omega-3 PUFAs in PCa prevention
or treatment.
Cholesterol
Many pre-clinical studies have shown that the accumu-
lation of cholesterol contributes to the progression of
PCa [74-76]. It was suggested that a high cholesterol in
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through the upregulation of cholesterol synthesis, inflam-
matory pathways [77] and intratumoral steroidogenesis
[78]. According to a recent study with 2,408 men sched-
uled for biopsy, serum cholesterol was independently as-
sociated with prediction of PCa risk [79]. Consistent with
the cholesterol findings, usage of the cholesterol lower-
ing drug statin post radical prostatectomy (RP) was sig-
nificantly associated with reduced risk of biochemical
recurrence in 1,146 radical prostatectomy patients [80].
Another study also showed that statins may reduce PCa
risk by lowering progression [81]. Although the mech-
anism has not been established, more recent studies
also showed that a low high-density lipoprotein (HDL)
cholesterol level was associated with a higher risk for
PCa and, thus, a higher HDL was protective [81-84].
These findings support the notion that a heart-healthy
dietary intervention that lowers cholesterol may benefit
prostate health also.
Vitamins and minerals
Herein we will review the recent data on vitamins A, B
complex, C, D, E, and K and selenium. In the two large
clinical trials: the Carotene and Retinol Efficacy Trial
(CARET; PCa was a secondary outcome) and the National
Institutes of Health-American Association of Retired
Persons (NIH-AARP) Diet and Health prospective co-
hort study, excessive multivitamin supplementation was
associated with a higher risk of developing aggressive PCa,
particularly among those taking individual β-carotene sup-
plements [85,86]. Similarly, high serum β-carotene levels
were associated with a higher risk for PCa among 997
Finnish men in the Kuopio Ischaemic Heart Disease Risk
Factor cohort [87]. However, β-carotene supplement was
not found to affect risk for lethal PCa during therapy [88],
or in the Danish prospective cohort study of 26,856 men
[89]. Circulating retinol also was not associated with PCa
risk in a large case–control study [90]. Thus, the associ-
ation between vitamin A and PCa is still unclear.
Preclinical evidence suggests folate depletion may slow
tumor growth, while supplementation has no effect on
growth or progression, but may directly lead to epige-
netic changes via increases in DNA methylation [91].
Two meta-analyses also showed that circulating folate
levels were positively associated with an increased risk of
PCa [92,93], while dietary or supplemental folate had no
effect on PCa risk [94] in a cohort study with 58,279
men in the Netherlands [95] and a case–control study
in Italy and Switzerland [96]. In fact, one study of a co-
hort of men undergoing radical prostatectomy at sev-
eral Veterans Administration facilities across the US
even showed that higher serum folate levels were as-
sociated with lower PSA and, thus, lower risk for bio-
chemical failure [97]. Another study using data fromthe 2007 to 2010 National Health and Nutrition Examin-
ation Survey showed that a higher folate status may be
protective against elevated PSA levels among 3,293 men,
40-years old and older, without diagnosed PCa [98]. It was
suggested that folate may play a dual role in prostate car-
cinogenesis and, thus, the complex relationship between
folate and PCa awaits further investigation [99].
Despite the potential role of vitamin C (ascorbic acid)
as an antioxidant in anticancer therapy, trials examining
dietary intake or supplementation of vitamin C are few.
A RCT showed no effect of vitamin C intake on PCa risk
[89]. Furthermore, vitamin C at high doses may act more
as a pro-oxidant than antioxidant, complicating the re-
search design and interpretation.
The primary active form of vitamin D, 1,25 dihydroxy-
vitamin D3 (calcitriol) aids in proper bone formation, in-
duces differentiation of some immune cells, and inhibits
pro-tumor pathways, such as proliferation and angiogen-
esis, and has been suggested to benefit PCa risk [100];
however, findings continue to be inconclusive. More re-
cent studies found that increased serum vitamin D levels
were associated with decreased PCa risk [101,102]. Fur-
ther, supplementing vitamin D may slow PCa progres-
sion or induce apoptosis in PCa cells [103-105]. Other
studies, however, reported either no impact of vitamin D
supplement on PSA [106] or no effect of vitamin D sta-
tus on PCa risk [107,108]. Some studies contrarily re-
ported that a lower vitamin D status was associated with
a lower PCa risk in older men [109], or a higher serum
vitamin D was associated with a higher PCa risk [110,111].
A study even suggested that a ‘U’ shaped relationship may
exist between vitamin D status and PCa and the optimal
range of circulating vitamin D for PCa prevention may be
narrow [112]. This is consistent with the findings for other
nutrients that a greater intake of a favorable nutrient may
not always be better.
A recent study showed that the association between
vitamin D and PCa was modulated by vitamin D-binding
protein [113] which may have partially explained the pre-
vious inconsistent findings. Further, a meta-analysis in-
vestigating the association between Vitamin D receptor
(VDR) polymorphisms (BsmI and FokI) and PCa risk re-
ported no relationship with PCa risk [114]. Thus, the role
of vitamin D in PCa remains unclear.
In a large randomized trial with a total of 14,641 US
male physicians ≥50-years old, participants randomly re-
ceived 400 IU of vitamin E every other day for an overall
mean of 10.3 (13.8) years. Vitamin E supplementation had
no immediate or long-term effects on the risk of total can-
cers or PCa [115]. However, a moderate dose of vitamin E
supplement (50 mg or about 75 IU) resulted in lower PCa
risk among 29,133 Finnish male smokers [116]. Multiple
preclinical studies suggest vitamin E slows tumor growth,
partly due to inhibiting DNA synthesis and inducing
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have been less than supportive. Two observational studies
(the Cancer Prevention Study II Nutrition Cohort and the
NIH-AARP Diet and Health Study) both showed no asso-
ciation between vitamin E supplementation and PCa risk
[118,119]. However, a higher serum α-tocopherol but not
the γ-tocopherol level was associated with decreased risk
of PCa [120,121] and the association may be modified
by genetic variations in vitamin E related genes [122].
On the contrary, a prospective randomized trial, the Sel-
enium and Vitamin E Cancer Prevention Trial (SELECT),
showed vitamin E supplementation significantly increased
PCa risk [123] and that a higher plasma α-tocopherol level
may interact with selenium supplements to increase high
grade PCa risk [124]. This finding is consistent with a
case-cohort study of 1,739 cases and 3,117 controls that
showed vitamin E increased PCa risk among those with
low selenium status but not those with high selenium
status [125]. Thus, more research is needed to examine
the association between vitamin E and PCa and the
dose effect and interaction with other nutrients should
be considered.
Vitamin K has been hypothesized to help prevent PCa
by reducing bioavailable calcium. Preclinical studies show
the combination of vitamins C and K have potent anti-
tumor activity in vitro and act as chemo- and radiosensiti-
zers in vivo [126]. To date, few studies have investigated
this, although one study using the European Prospective
Investigation into Cancer and Nutrition (EPIC)-Heidelberg
cohort found an inverse relationship between vitamin K (as
menaquinones) intake and PCa incidence [127].
Little to no preclinical studies have been conducted to
examine the role of calcium with PCa. Retrospective and
meta-analyses suggest increased or reduced PCa risk
with increased calcium intake, while others suggest no
association [128,129]. Another study suggests a ‘U’-shaped
association, where very low calcium levels or supplemen-
tation are both associated with PCa [130].
Selenium, on the other hand, has been hypothesized
to prevent PCa. While in vitro studies suggested that
selenium inhibited angiogenesis and proliferation while
inducing apoptosis [131], results from SELECT showed
no benefit of selenium alone or in combination with
vitamin E for PCa chemoprevention [123]. Further, sel-
enium supplementation did not benefit men with low
selenium status but increased the risk of high-grade
PCa among men with high selenium status in a ran-
domly selected cohort of 1,739 cases with high-grade
(Gleason 7–10) PCa and 3,117 controls [125]. A prospec-
tive Netherlands Cohort Study, which included 58,279
men, 55- to 69-years old, also showed that toenail selen-
ium was associated with a reduced risk of advanced PCa
[132]. Further research is needed to clarify the role of
selenium with PCa.Phytochemicals
Along with vitamins and minerals [2], plants contain phy-
tochemicals with potential anti-cancer effects. Typically
not considered essential compounds, phytochemicals have
antioxidant and anti-inflammatory properties.
Silibinin is a polyphenolic flavonoid found in the seeds
of milk thistle. It has been shown in vitro and in vivo to
inhihit PCa growth by targeting epidermal growth factor
receptor (EGFR), IGF-1 receptor (IGF-1R), and nuclear
factor-kappa B (NF-kB) pathways [133,134]. A recent
study showed that silibinin may be useful in PCa pre-
vention by inhibiting TGFβ2 expression and cancer-
associated fibroblast (CAF)-like biomarkers in the human
prostate stromal cells [135]. Thus, silibinin is a promising
candidate as a PCa chemopreventive agent that awaits fur-
ther research.
Curcumin is used as food additive in Asia and as an
herbal medicine for inflammation [136]. In vitro, curcu-
min inhibits the pro-inflammatory protein NF-κB while
inducing apoptosis through increased expression of pro-
apoptotic genes [137]. In vivo, curcumin slows PCa growth
in mice while sensitizing tumors to chemo- and radiothe-
rapies [136]; however, no human trial has examined its
impact on PCa.
Pomegranate
The peel and fruit of pomegranates and walnuts are rich
in ellagitannins (punicalagins). These phytochemicals are
readily metabolized to the active form ellagic acid by gut
flora [138]. Preclinical experiments show ellagitannins in-
hibit PCa proliferation and angiogenesis under hypoxic
conditions and induce apoptosis [137,138]. In prospective
trials in men with a rising PSA after primary treatment,
pomegranate juice or POMx, a commercially available
pomegranate extract, increased the PSA doubling time
relative to baseline [139,140], although no trials included a
placebo group. Results are pending from a prospective
placebo RCT using pomegranate extract in men with a
rising PSA. However, in a placebo controlled trial, two
pills of POMx daily for up to four weeks prior to radical
prostatectomy had no impact on tumor pathology or oxi-
dative stress or any other tumor measures [141].
Green tea
Green tea contains a number of antioxidant polyphe-
nols including catechins, such as epigallocatechin gallate
(EGCG), epigallocatechin (EGC), (−)-epicatechin-3-gallate
(ECG) and (−)-epicatechin. Preclinical studies suggest
EGCG inhibits PCa growth, induces intrinsic and ex-
trinsic apoptotic pathways and decreases inflammation
by inhibiting NFkB [137]. Furthermore, the antioxidant
properties of EGCG are 25 to 100 times more potent
than vitamins C and E [131]. In a prospective randomized
preprostatectomy trial, men consuming brewed green tea
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nols in their prostate tissue [142]. In a small proof-of-
principle trial with 60 men, daily supplementation of
600 mg green tea catechin extract reduced PCa incidence
by 90% (3% versus 30% in the placebo group) [143].
Another small trial also showed that EGCG supplement
resulted in a significant reduction in PSA, hepatocyte
growth factor and vascular endothelial growth factor in
men with PCa [144]. These studies suggest green tea
polyphenols may lower PCa incidence and reduce PCa
progression but more research is needed to confirm
and clarify its mechanism [137,143,145].
Resveratrol
While most in vitro studies suggest resveratrol inhibits
PCa growth [146-148], resveratrol suppresses tumor
growth in some [137] but not all animal models [149],
possibly due to limited bioavailability [150,151]. To date,
there are no clinical trials investigating the preventive
or therapeutic effects of resveratrol on PCa.
Zyflamend
Zyflamend is an anti-inflammatory mixture of herbs that
has been shown to reduce PCa progression by lowering
the expression of markers including pAKT, PSA, histone
deacetylases and androgen receptor in animal models
and PCa cell line [152-154]. Despite its anti-cancer po-
tential [155], very few studies have been conducted in
humans [156,157]. In an open-label Phase I trial of 23
patients with high-grade prostatic intraepithelial neopla-
sia, Zyflamend alone or in conjunction with other diet-
ary supplements for 18 months reduced the risk for
developing PCa [156]. More RCTs in humans are nee-




Fruits and vegetables are rich sources of vitamins, min-
erals and phytochemicals. Several epidemiologic studies
found inverse relationships between total fruit and vege-
table intake [158], and cruciferous vegetable intake and
PCa risk [159,160]. Allium vegetables, such as garlic,
leeks, chives, and shallots, contain multiple sulfurous
phytochemicals that were suggested to enhance the im-
mune system, inhibit cell growth, modulate expression
of androgen-responsive genes and induce apoptosis
[161]. Although the number of published studies is lim-
ited, both preclinical and epidemiologic data suggest al-
lium vegetable intake may be protective against PCa,
particularly localized disease [162]. A randomized trial
with 199 men also found that a blend supplement of po-
megranate, green tea, broccoli and turmeric significantly
reduced the rate of rise in PSA in men with PCa [163].Tomatoes and tomato products
A number of studies have examined the association
between tomatoes and tomato products with PCa but
the findings are inconclusive. The antioxidant lycopene,
which is rich in tomatoes, has also been studied specif-
ically for its impact on PCa. In vitro, lycopene halts the
cell cycle in several PCa cell lines and decreases IGF-1
signaling by inducing IGF-1 binding proteins [131].
While some animal studies found lycopene specifically
slows PCa growth [164] or reduces PCa epithelial cells
at stages of initiation, promotion and progression [165],
two studies found conflicting findings between tomato
paste and lycopene [166,167]. Prospective human stu-
dies found higher lycopene consumption [168,169] or
higher serum levels were associated with lower PCa risk
[170], but others have not [171,172]. Prostatic lycopene
concentration below a 1 ng/mg threshold was associated
with PCa at six-month follow-up biopsy (P = 0.003) [173].
Two short-term preprostatectomy trials using tomato
sauce or lycopene supplementation demonstrated lyco-
pene uptake in prostate tissue and antioxidant and poten-
tial anticancer effects [174,175]. While several clinical
trials suggested an inverse relationship between lycopene
supplementation, PSA levels and decreases in cancer-
related symptoms [171,176], no large-scale randomized
trials have tested the role of lycopene or tomato products
on PCa prevention or treatment.
Coffee
Coffee contains caffeine and several unidentified phenolic
compounds that may serve as antioxidants. Epidemio-
logical studies suggest an inverse relationship between cof-
fee consumption and PCa risk, mainly for advanced or
lethal stage disease, and the findings were independent of
caffeine content [177,178]. Although several epidemio-
logical studies [179-182] found no association between
coffee consumption and PCa risk, a recent meta-analysis
of prospective studies concluded that coffee consumption
may reduce PCa risk [183]. The potential mechanism(s)
and pathway(s) involved are unknown but may include
antioxidant, anti-inflammatory effects, glucose and insulin
metabolism, and potential impact on IGF-I and circulating
sex hormones.
Dietary patterns
Even though many single nutrients or food factors have
been examined for their impact or association with PCa
risk or progression, the results have largely been incon-
clusive. A potential reason for the inconsistency is the
fact that the impact of single nutrient or food factor may
be too small to be detected. In addition, nutrients naturally
existing in foods often are highly correlated and may in-
teract with each other and, thus, affect the impact on PCa.
Thus, dietary pattern analysis has received an increasing
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sults have been inconclusive. In a cohort of 293,464 men, a
high dietary quality, as indicated by the Healthy Eating
Index (HEI) score, was associated with a lower risk of total
PCa risk [70]. The Mediterranean diet, which is high in
vegetables, olive oil, complex carbohydrates, lean meats
and antioxidants, is consistently recommended to patients
for prevention of cardiovascular disease and obesity [184],
and may show promise in PCa prevention [185]. Fish and
omega-3 fatty acid consumption in the Mediterranean pat-
tern were significantly and inversely associated with fatal
PCa risk. In addition, adherence to the Mediterranean diet
after diagnosis of non-metastatic PCa was associated with
lower overall mortality [186]. Whereas, a Western pattern
with high intakes of red meats, processed meats, fried fish,
chips, high-fat milk and white bread, was associated with a
higher risk for PCa [187].
Furthermore, Asian countries with high consumption
of omega-3 PUFAs, soy and green tea-based phytoche-
micals, have lower PCa incidences versus countries con-
suming a ‘Western-style’ diet [188]. However, not all
studies [189-191] supported an association between
certain dietary pattern and risk of PCa. It is possible
that the methodology used in identifying dietary pat-
terns may not have captured all the dietary factors asso-
ciated with PCa risk. Alternatively, each dietary pattern
may contain both beneficial and harmful components
resulting in an overall null association. More research
is needed to continue searching for dietary patterns
that combine most of the beneficial nutrients/food fac-
tors for PCa and limit most of the negative nutrients/
food factors.
Future direction for clinical trials
Based on the multitude of epidemiologic, preclinical and
clinical trials described in this review, dietary interven-
tions for the prevention and treatment of PCa hold great
promise. In addition, several dietary factors and vita-
mins/supplements may be associated with PCa risk and/
or progression of disease. Prospective randomized trials
are clearly indicated to identify specific nutrients or
combination therapies for the prevention and treatment
of PCa.
Recently, active surveillance (AS) has emerged as a vi-
able option for men with lower risk PCa. Men on AS are
motivated to adhere to diet and lifestyle modifications
[192], making this subset a good target for dietary in-
tervention and quality of life trials [193]. PCa survivors
who are more active and report ‘healthy’ eating habits
(that is, consuming low-fat, low-refined carbohydrate diets
rich in fruits and vegetables) have better overall quality of
life versus their inactive, unhealthy counterparts [194].
Thus, more randomized trials are warranted to determine
the overall long-term effects of dietary intervention in thispopulation. Specifically, key questions to address in future
trials are: 1) Can dietary interventions delay the need for
treatment in men on AS; 2) Can dietary interventions pre-
vent recurrence for men after treatment; 3) Can dietary
interventions delay progression among men with recur-
rent disease and, thus, delay the need for hormonal ther-
apy; 4) Can dietary interventions reduce the side effects of
PCa treatments including hormonal therapy and newer
targeted therapies; and 5) Is there any role for dietary in-
terventions alone or combined with targeted therapies in
men on hormonal therapy to prevent castrate-resistance
or after the emergence of castrate resistance disease? Be-
cause increasing evidence shows that metabolic abnormal-
ities increase risk for PCa, lifestyle intervention that
improves metabolic profile is a win-win option for PCa
prevention and treatment [195,196].
Conclusions
Future research is required to determine the ideal diet
for PCa prevention or treatment. However, several die-
tary factors and some dietary patterns hold promise in
reducing PCa risk or progression and are consistent with
current dietary guidelines for Americans [197]. For coun-
seling patients on diet for primary and secondary PCa
prevention, many believe ‘heart healthy equals prostate
healthy.’ Thus, given the current inconclusive results,
the best dietary advice for PCa prevention or manage-
ment seems to include: increasing fruits and vegetables,
replacing refined carbohydrates with whole grains, redu-
cing total and saturated fat, reducing overcooked meats
and consuming a moderate amount of calories or redu-
cing carbohydrates with a primary goal of obtaining and
maintaining a healthy body weight.
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